

Level of SARS-CoV-2 IgG antibodies after two doses CoronaVac vaccine: Primarily report

Umut Binay (✉ devrimbinay@hotmail.com)

Erzincan Binali Yildirim University

Faruk Karakecili

Erzincan Binali Yildirim University

Orcun Barkay

Erzincan Binali Yildirim University

Ozlem Gul

Erzincan Binali Yildirim University

Cuma Mertoglu

Erzincan Binali Yildirim University

Research Article

Keywords: COVID-19, CoronaVac vaccine, SARS-CoV-2 IgG

Posted Date: April 12th, 2021

DOI: <https://doi.org/10.21203/rs.3.rs-388073/v2>

License:   This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

Abstract

Background: It is necessary to use an effective vaccine to end the COVID-19 pandemic. CoronaVac vaccine is used in our country and we aimed to examine the level of antibody development after the second dose.

Methods: This is a retrospective, cross-sectional research. The data of the people, who applied to a university hospital between January and March 2021, were analyzed. Those who had SARS-CoV-2 IgG and IgM measurement in the previous two weeks before the CoronaVac vaccine, and those who were both found negative and who had SARS-CoV-2 IgG and IgM measurement after the second dose of CoronaVac vaccine were included in the research. SARS-CoV-2 IgG/IgM were measured by VIDAS® (BioMérieux, Marcy-l'Etoile, France) device for the detection of spike protein specific IgG/IgM of SARS-CoV-2 in human serum with ELFA (Enzyme Linked Fluorescent Assay) technique.

Results: 75 people were included in this research. It was found that the individuals had SARS-CoV-2 IgG and IgM measurements between 14 and 21 days after the first dose of CoronaVac vaccine. It was observed that 12% (n = 9) of the cases had a history of COVID-19. The rate of positivity for SARS-CoV-2 IgG level after vaccination was 100%.

Conclusions: It can be said that two doses of CoronaVac vaccine create an effective humoral immunity.

Introduction

A new strain of coronavirus was identified as the cause of a series of pneumonia cases in Wuhan, a city in Hubei province of China, at the end of 2019. The virus spread rapidly all over the world, causing a global pandemic, and the pandemic still continues. The name of the virus was defined as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and the World Health Organization (WHO) defined the disease as COVID-19, which stands for 2019 coronavirus disease, in February 2020(1).

To prevent SARS-CoV-2 infection, vaccine development is considered as the most promising approach to control the pandemic and is followed by the whole world. By the end of 2020, several vaccines were ready to use in different parts of the world with emergency approval (2).

CoronaVac 600 SU/0.5 ml (Sinovac Life Sciences, Beijing, China) vaccine, which is an inactive COVID-19 vaccine has been used after obtaining emergency approval in our country (3). As of January 14, 2021, vaccination has been initiated for our population starting with healthcare workers (4). The vaccine, which was administered intramuscularly as 2 doses in 28 days, was shown to be safe and immunogenic in Phase 1 and 2 trials (5).

In this research, it was aimed to evaluate the effectiveness of the CoronaVac vaccine after two doses by examining the results of people who had SARS-CoV-2 immunoglobulin G (IgG) and immunoglobulin M (IgM) measurements in our hospital.

Materials And Methods

This is a retrospective, cross-sectional research and was conducted with the informed consent of all participants. Ministry of Health and Erzincan Binali Yildirim University (EBYU) ethics committee approvals have been obtained (Date: 22.03.2021 and Decision no: 05/27). All methods were performed in accordance with the relevant guidelines and regulations.

The data of the people who applied to the COVID-19 Antibody Polyclinic of EBYU Mengücek Gazi Training and Research Hospital between January and March 2021 were retrospectively analyzed; the people who met the inclusion criteria were detected and their data were collected. Accordingly, those who had SARS-CoV-2 IgG and IgM measurement in the previous two weeks before the CoronaVac vaccine, and those who were both found negative and who had SARS-CoV-2 IgG and IgM measurement after the second dose of CoronaVac vaccine were included in the research. People who had negative antibody results before vaccination but were not vaccinated and those who did not have a measurement of antibody levels after vaccination were not included in the research. The demographic data of the individuals (age, gender, presence of comorbidities, medications, etc.), whether they had COVID-19 and how long ago they had COVID-19 were evaluated. For the participants having a history of COVID-19; complete blood count (CBC), serum ferritin, C-reactive protein (CRP) and D-dimer levels' results were also collected.

75 people were included in this research. It was found that the individuals had SARS-CoV-2 IgG and IgM measurements between 14 and 21 days after the second dose of CoronaVac vaccine.

SARS-CoV-2 IgG and IgM measurements;

1. SARS-CoV-2 IgG was measured by VIDAS® (BioMérieux, Marcy-l'Etoile, France) device for the detection of spike protein specific IgG of SARS-CoV-2 in human serum with ELFA (Enzyme Linked Fluorescent Assay) technique.
2. SARS-CoV-2 IgM was measured by VIDAS® (BioMérieux, Marcy-l'Etoile, France) device for the detection of spike protein specific IgM of SARS-CoV-2 in human serum with ELFA (Enzyme Linked Fluorescent Assay) technique.

Interpretation of the results

The interpretation of the results according to the test value is as: <1,00 (negative) and > 1.00 (positive) (7).

CBC was measured by the Sysmex XN-1000 Hematology System (Sysmex Corporation, Kobe, Japan) automated blood counter. Serum ferritin level was measured by chemiluminescence immunoassay (Centaur XP, Siemens Healthcare, Germany). CRP was measured by the BN™ II System device by the

nephelometric method (Siemens, Munich, Germany). D-dimer level was measured from whole blood by the AQT90 flex Radiometer® (Bronshoj, Denmark) device.

Statistical Analysis

NCSS (NumberCruncher Statistical System) program was used for statistical analysis. Descriptive statistical methods (mean, standard deviation, median, frequency, percentage, minimum, maximum) were used while evaluating the study data. The suitability of quantitative data with normal distribution was tested by Shapiro-Wilk, Kolmogorov-Smirnov tests and graphical analysis. Mann-Whitney U test was used for the comparison of quantitative variables that did not show normal distribution between two groups. Spearman correlation analysis was used to evaluate the relationships between quantitative variables. Statistical significance was accepted as $p < 0.05$.

Results

The research was carried out in EBYU Mengücek Gazi Training and Research Hospital between the dates of 01.01.2021–31.03.2021. 50.7% (n = 38) of the cases were female and 49.3% (n = 37) were male. The ages of the cases ranged from 23 to 74, with a mean age of 38.41 ± 8.50 .

It was observed that 12% (n = 9) of the cases had a history of COVID-19. The duration of having COVID-19 ranges from 2 to 8 months before the vaccination, with an average of 4.28 ± 2.28 months.

In all cases (n = 75), it was observed that SARS CoV-2 IgG level was positive after 2 doses of vaccine. The IgG levels of the cases ranged from 1.22 to 45, and the mean value was found to be 10.81 ± 8.04 (Table 1). SARS CoV-2 IgM levels of the cases were found to be negative.

Table 1
Distribution of Descriptive Features

Age (year)	Min-Max (Median)	23–74 (39)
	<i>Mean ± SD</i>	38.41 ± 8.50
Gender	Female	38 (%50.7)
	Male	37 (%49.3)
History of COVID-19	No	66 (%88)
	Yes	9 (%12)
The duration of having COVID-19(month)	<i>Min-Max (Median)</i>	2–8 ay (3 ay)
	<i>Mean ± SD</i>	4.28 ± 2.28
SARS-CoV-2 IgG Result after two doses vaccine		
	Positive	75 (%100)
	<i>Min-Max (Median)</i>	1.22-45 (10.33)
	<i>Mean ± SD</i>	10.81 ± 8.04

The leukocyte counts of people having a history of COVID-19 during the disease period varied between 4.300 and 9.800/mm³, with an average of 7055.56 ± 1636.39/mm³; their platelet counts between 197.000 and 342.000/μL, with an average of 248000.00 ± 49272.20/μL; hemoglobin levels varied between 11.1 and 17.3 g/dL, with an average of 14.70 ± 1.95 g/dL; lymphocyte counts varied between 510 and 3880/μL, with an average of 1897.78 ± 1066.84/μL; neutrophil counts varied between 1650 and 6220/μL, with an average of 4213.33 ± 1481.07/μL; serum CRP levels varied between 3 and 23 mg/L, with an average of 6.63 ± 7.33 mg/L; D-Dimer levels varied between 128 and 690 μg/L, with an average of 345.22 ± 175.68 μg/L and ferritin levels ranged from 6 to 150 ng/mL, with an average of 70.44 ± 48.47 ng/mL (Table 2).

Table 2
Distribution of Laboratory Results of Cases with History of COVID-19

Leukocyte Counts(/mm ³)	<i>Min-Max (Median)</i>	4300–9800 (6800)
	<i>Mean ± SD</i>	7055.56 ± 1636.39
Platelet Counts(/μL)	<i>Min-Max (Median)</i>	197000–342000 (226000)
	<i>Mean ± SD</i>	248000.00 ± 49272.20
Hemoglobin levels(g/dL)	<i>Min-Max (Median)</i>	11,1-17.3 (15.1)
	<i>Mean ± SD</i>	14.70 ± 1.95
Lymphocyte Counts(/μL)	<i>Min-Max (Median)</i>	510–3880 (1640)
	<i>Mean ± SD</i>	1897.78 ± 1066.84
Neutrophil Counts(/μL)	<i>Min-Max (Median)</i>	1650–6220 (4610)
	<i>Mean ± SD</i>	4213.33 ± 1481.07
CRP Levels(0–5 mg/L)	<i>Min-Max (Median)</i>	3–23 (3)
	<i>Mean ± SD</i>	6.63 ± 7.33
D-Dimer Levels(μg/L)	<i>Min-Max (Median)</i>	128–690 (342)
	<i>Mean ± SD</i>	345.22 ± 175.68
Ferritin Levels(ng/mL)	<i>Min-Max (Median)</i>	6-150 (50)
	<i>Mean ± SD</i>	70.44 ± 48.47
<i>CRP: C-ReactiveProtein</i>		

The age and gender distributions of the cases according to the SARS CoV-2 IgG levels after vaccination did not show a statistically significant difference ($p > 0.05$). According to the presence of Covid-19 history, no statistically significant difference was found between the post-vaccination SARS CoV-2 IgG levels of the cases ($p > 0.05$) (Table 3).

Table 3
Comparisons by Post Vaccine SARS CoV-2 IgG Levels

		Post Vaccine SARS CoV-2 IgG Levels		
		Min-Max (Median)	Mean ± SD	P
Gender	Female (n = 38)	1.3–45 (9.6)	10.86 ± 8.61	†0.878
	Male (n = 37)	1.2–30 (10.6)	10.76 ± 7.54	
History of COVID-19	No (n = 66)	1.3–45 (10.4)	10.90 ± 7.96	†0.648
	Yes (n = 9)	1.2–30 (6.5)	10.13 ± 9.08	
		<i>r</i>	<i>P</i>	
Age		-0,053	0,653	
† <i>MannWhitney U Test r = Spearman's Correlation Coefficient</i>				

Discussion

One of the important ways to control the COVID-19 pandemic is to produce an effective vaccine. Currently, various vaccines generated by different methods are being used all over the world with emergency use approval (2). When the effectiveness of vaccines in use are examined; Pfizer / BioNTech, Gamaleya, Moderna and AstraZeneca announced the vaccine efficiency as 95%, 92%, 94.5%, 70%, respectively (8, 9, 10). For the CoronaVac vaccine, efficacy statements have been received from different countries at different rates (50.4%, 65.3, 78, 91.25), and these data have not been published yet (11, 12).

Recently, different SARS-CoV-2 variants have brought some reservations about the effectiveness of vaccines. It is thought that the immunity created by the vaccine against some variants may not be effective. It is stated that especially mRNA vaccines will need to be revised (13–15). However, Iversen and Bavari stated that compared to vaccines targeting only spike protein, inactivated vaccines would provide additional benefit as they target many SARS-CoV-2 proteins (16). Another drawback regarding vaccines is whether or not a booster dose will be required. In a study conducted with healthcare workers infected with SARS-CoV-2, it was shown that neutralizing antibody levels decreased over time. Therefore, it has been suggested that booster vaccination may be required periodically (17).

SARS-CoV-2 vaccines have been developed very rapidly and because of this they have brought some concerns in terms of long-term side effect profile. Anaphylaxis is one of the important life-threatening side effects and there are concerns that it may be more likely to be seen in mRNA vaccines (12, 18–20).

CoronaVac 600 SU/0.5 ml (Sinovac Life Sciences, Beijing, China) vaccine, which is an inactive COVID-19 vaccine is being used after obtaining emergency use approval in our country (3). The vaccine is administered intramuscularly in 2 doses, 28 days apart. When the literature was examined, it was found that real-life data on CoronaVac vaccine was not shared before. The data in our research is the first real-life data of CoronaVac vaccine and is important in this regard.

Another issue is how protective the antibodies against SARS-CoV-2 are. In the study conducted by Lumley et al., it was shown that the incidence of COVID-19 in healthcare workers with SARS-CoV-2 IgG positivity was significantly lower. Antibodies against spike protein and / or nucleocapsid have been shown to be protective (21). In the study conducted by Borgonovo et al., it was shown that IgG formed against spike protein continued for 7 months and symptomatic COVID-19 infection did not develop in these people (22). In another study by Zhang et al., it was shown that B lymphocyte response developed in the first 14 days after a single dose of CoronaVac vaccine, but T lymphocyte response developed after the second dose (23). When the data of our study were examined, the rate of antibody formation after the second dose of vaccination in all individuals was found to be 100%. These data show that the CoronaVac vaccine is effective after two doses.

There are some limitations in our study. One of them is being conducted in a single center with a small number of people. In addition, cellular immunity was not evaluated and protection was measured only by the antibody level. In this context, multi-centered studies consisting of larger groups evaluating antibody and cellular immune response level after first and second dose of vaccination are needed.

In conclusion, antibody development level was found to be 100% after two doses of CoronaVac vaccine. It can be said that two doses of CoronaVac vaccine create an effective humoral immunity. Therefore, two doses of CoronaVac vaccine application is effective against SARS-CoV-2.

Declarations

Acknowledgments

There is no special thanks.

Declaration of Interest Statement

The authors have no conflicts of interest.

References

1. -World Health Organization. Director-General's remarks at the media briefing on 2019-nCoV on 11 February 2020. <http://www.who.int/dg/speeches/detail/who-director-general-s-remarks-at-the-media-briefing-on-2019-ncov-on-11-february-2020> (Accessed on 20.02.2021)

2. -World Health Organization. Draft landscape of COVID-19 candidate vaccines.
<https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines>
 (Accessed on 20.02.2021)
3. -<https://www.titck.gov.tr/haber/kamuoyunun-dikkatine-13012021185623> (Accessed on 20.02.2021)
4. -<https://www.bbc.com/turkce/haberler-turkiye-55657237> (Accessed on 21.02.2021)
5. Zhang, Y., Zeng, G., Pan, H., Li, C., Hu, Y., Chu, K., ... Zhu, F. (2020). Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. *The Lancet Infectious Diseases*.
6. Wu, Z., Hu, Y., Xu, M., Chen, Z., Yang, W., Jiang, Z., ... Yin, W. (2021). Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. *The Lancet Infectious Diseases*.
7. Renard, N., Daniel, S., Cayet, N., Pecquet, M., Raymond, F., Pons, S., ... Berthier, F. (2021). Performance characteristics of the VIDAS® SARS-CoV-2 IgM and IgG serological assays. *Journal of clinical microbiology*.
8. Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., ... Gruber, W. C. (2020). Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. *New England Journal of Medicine*, *383*(27), 2603–2615.
9. Voysey, M., Clemens, S. A. C., Madhi, S. A., Weckx, L. Y., Folegatti, P. M., Aley, P. K., ... Bijker, E. (2021). Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. *The Lancet*, *397*(10269), 99–111.
10. -Knoll, M. D. & Wonodi, C. Oxford–AstraZeneca COVID-19 vaccine efficacy. *The Lancet*. **397** (10269), 72–74 (2021).
11. Sinovac, B. B. C. Brazil results show Chinese vaccine 50.4% effective.
<https://www.bbc.com/news/world-latin-america-55642648> (Accessed on 22.02.2020).
12. -Mallapaty, S. China COVID vaccine reports mixed results - what does that mean for the pandemic? *Nature*. 2021 Jan 15. doi: 10.1038/d41586-021-00094-z. Epub ahead of print. PMID: 33452510.
13. -Moore, J. P. & Offit, P. A. SARS-CoV-2 vaccines and the growing threat of viral variants. *JAMA*. **325** (9), 821–822 (2021).
14. Garcia-Beltran, W. F., Lam, E. C., Denis, K. S., Nitido, A. D., Garcia, Z. H., Hauser, B. M., ... Balazs, A. B. (2021). Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity. *Cell*.
15. Xie, X., Liu, Y., Liu, J., Zhang, X., Zou, J., Fontes-Garfias, C. R., ... Shi, P. Y. (2021). Neutralization of SARS-CoV-2 spike 69/70 deletion, E484K and N501Y variants by BNT162b2 vaccine-elicited sera. *Nature Medicine*, 1–2.

16. -Iversen, P. L. & Bavari, S. (2021). Inactivated COVID-19 vaccines to make a global impact. *The Lancet Infectious Diseases*.
17. Marot, S., Malet, I., Leducq, V., Zafilaza, K., Sterlin, D., Planas, D., ... Marcelin, A. G. (2021). Rapid decline of neutralizing antibodies against SARS-CoV-2 among infected healthcare workers. *Nature communications*, 12(1), 1–7.
18. -Castells, M. C. & Phillips, E. J. Maintaining safety with SARS-CoV-2 vaccines. *New England Journal of Medicine*. **384** (7), 643–649 (2021).
19. -CDC COVID-19 Response Team, & Food and Drug Administration (2021). Allergic Reactions Including Anaphylaxis After Receipt of the First Dose of Pfizer-BioNTech COVID-19 Vaccine - United States, December 14–23, 2020. *MMWR. Morbidity and mortality weekly report*, 70(2), 46–51. <https://doi.org/10.15585/mmwr.mm7002e1>
20. -Zellweger, R. M., Wartel, T. A., Marks, F., Song, M. & Kim, J. H. Vaccination against SARS-CoV-2 and disease enhancement—knowns and unknowns. *Expert Review of Vaccines*. **19** (8), 691–698 (2020).
21. Lumley, S. F., O'Donnell, D., Stoesser, N. E., Matthews, P. C., Howarth, A., Hatch, S. B., ... Eyre, D. W. (2020). Antibody status and incidence of SARS-CoV-2 infection in health care workers. *New England Journal of Medicine*.
22. -Borgonovo, F. *et al.* (2021). Is COVID-19 severity associated with anti-spike antibody duration? Data from the ARCOVID prospective observational study. *The Journal of infection*, S0163-4453(21)00048 – 7. Advance online publication. <https://doi.org/10.1016/j.jinf.2021.01.023>
23. Zhang, H., Hu, Y., Jiang, Z., Shi, N., Lin, H., Liu, Y., ... Xia, Q. (2021). Single-Cell Sequencing and Immune Function Assays of Peripheral Blood Samples Demonstrate Positive Responses of an Inactivated SARS-CoV-2 Vaccine.